Recursion Appoints Fred Hassan as Chair Amid Positive FAP Clinical Data
What happened
Recursion Pharmaceuticals appointed Fred Hassan as non-executive chair of the company. The company also reported updated Phase II TUPELO data for its investigational treatment for familial adenomatous polyposis (FAP). This treatment showed that 87% of evaluable patients had reductions in total polyp burden after 12 weeks of treatment.
From themarketsdaily.com
Why it matters
The appointment of Fred Hassan, who previously served as CEO of Schering-Plough and held board roles at Amgen and BridgeBio, adds high-profile governance to Recursion. This follows the release of positive clinical results for its FAP treatment and the company's extension of its cash runway into 2029.
From themarketsdaily.com
Who's involved
- Fred HassanAppointed non-executive chair of Recursion.
- Recursion (United States)Company that appointed Fred Hassan and reported clinical results.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Recursion (United States)Speculative
Recursion could see its valuation and funding access increase due to the positive clinical data and the high-profile chair appointment.
Keep exploring
The entities involved
-
Fred Hassan
American businessman
Nothing else this week.
-
Recursion (United States)
company in Salt Lake City, United States
Nothing else this week.